C4 Therapeutics, Inc. (CCCC) Form 10-Q — Aug 11, 2026
C4 Therapeutics reported Q2 2026 collaboration revenue of $6.6 million, up from $6.5 million a year ago, driven by $2.7 million recognized under the new Roche degrader-antibody conjugate agreement signed in April 2026. Net loss narrowed to $23.6 million ($0.18 per share) from $26.0 million ($0.37 per share) in the year-ago quarter. The company ended the quarter with $300.4 million in cash, cash equivalents and marketable securities, which it believes will fund planned operating expenses to the end of 2028. The runway was supported by Roche's $20.0 million upfront payment and $33.5 million of net proceeds from at-the-market share sales at a weighted average price of $3.71.
Key figures
- Revenue
- 6641000
- Guidance
- Cash, cash equivalents and marketable securities of $300.4 million expected to fund planned operating expenses to the end of 2028
- Revenue Yoy
- +2.8% (Q2 2026 vs Q2 2025)
- Total Assets
- 359404000
- Cash Position
- 78610000
- Shares Outstanding
- 123025136
- Q2 2025 revenue
- 6463000
- Six month revenue
- 12793000
- Accumulated deficit
- 787457000
- Six month revenue yoy
- -6.6%
- Atm weighted avg price
- 3.71
- Deferred revenue total
- 40375000
- Atm shares sold h1 2026
- 9273620
- Atm net proceeds h1 2026
- 33548000
- Shares growth six months
- 96,914,418 to 122,905,756 (~27%)
- Roche dac upfront payment
- 20000000
- Offering 2025 net proceeds
- 116900000
- Roche dac milestone potential
- over $1.0 billion in the aggregate
- Biogen milestone earned feb 2026
- 2000000
- Potential warrant exercise proceeds
- 341700000
- Anti dilutive common stock equivalents
- 118692207
- Roche dac unsatisfied transaction price
- 17300000
- Cash cash equivalents marketable securities
- 300400000
- Marketable securities weighted avg maturity
- 0.7 years
- Unsatisfied transaction price all collaborations
- 146600000
Price after filing
Close on the filing date to close N calendar days later (from $3.73). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.